Address
Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
United StatesDescription
Founded in 1887, the National Institutes of
Health today is one of the world's foremost medical research
centers, and the Federal focal point for medical research in the
United States. The NIH, comprising 27 separate Institutes and
Centers, is one of eight health agencies of the Public Health
Service which, in turn, is part of the U.S. Department of Health
and Human Services (HHS). The NIH distributes 80 percent of its
funding in extramural research grants and about 10 percent in its
in-house intramural research program. The intramural research
program has produced a rich portfolio of over 3,000 active patents
and over 1,300 active licenses that is managed by the Office of
Technology Transfer (OTT).
Mission
NIH is the steward of medical and behavioral
research for the Nation. Its mission is science in pursuit of
fundamental knowledge about the nature and behavior of living
systems and the application of that knowledge to extend healthy
life and reduce the burdens of illness and disability. The NIH
Office of Technology Transfer evaluates, protects, licenses,
monitors, and manages the wide range of NIH and FDA discoveries,
inventions, and other intellectual property as mandated by the
Federal Technology Transfer Act and related legislation. To
accomplish its mission, OTT oversees patent prosecution and
negotiates and monitors licensing agreements. OTT performs similar
functions for patenting and licensing activities for the Food and
Drug Administration (FDA), another component of HHS. Other major
functions within OTT include the development of technology transfer
policies for NIH and the implementation of decisions by the
Technology Transfer Policy Board.
Technology Disciplines
Displaying 1 - 10 of 5469
1,2-Dihydroellipticines with Activity Against CNS-Specific Cancer Cell Lines
Description:
The present invention is directed, in general, to methods for treating human cancers and in particular to new compounds which cross the blood brain barrier and retain activity against CNS specific cancer cell lines, to pharmaceutical formulations containing such compounds, and to methods for the treatment of cancer.
The 2-methylellipticinium salts offer remarkable examples of compounds that have shown selective cytotoxicity for the CNS cancer cell lines. In 17 assays, 6 showed selectivity for the CNS subpanel at every level of the dose-response curve down to 10-7M. Both the 9-methyl and the 9-chloro analogues also displayed good CNS selectivity at the levels for growth inhibition and cytostasis.
Abstract
The present invention is directed, in general, to methods for treating human cancers and in particular to new compounds which cross the blood brain barrier and retain activity against CNS specific cancer cell lines, to pharmaceutical formulations containing such compounds, and to methods for the treatment of cancer.
The 2-methylellipticinium salts offer remarkable examples of compounds that have shown selective cytotoxicity for the CNS cancer cell lines. In 17 assays, 6 showed selectivity for the CNS subpanel at every level of the dose-response curve down to 10-7M. Both the 9-methyl and the 9-chloro analogues also displayed good CNS selectivity at the levels for growth inhibition and cytostasis.
Rudiger Haugwitz (NCI)➽ more inventions...
U.S. Pat:5,272,146issued 1993-12-21
U.S. Pat:5,441,941issued 1995-08-15
This research is described, in part, in Jurayj et al., "Design and Synthesis of Ellipticinium Salts and 1,2-Dihydroellipticines with High Selectivities against Human CNS Cancers in vitro," J. Med. Chem. 37(14):2190-2197, 1994.
Admin. Licensing Specialist (ALS),
Email:
Phone:
E-110-1992/0
Updated:Oct 1, 2005
Details
| Internal Lab Reference ID | E-110-1992/0 |
| Inventors | Rudiger Haugwitz |
1,2-Dihydroellipticines with Activity Against CNS-Specific Cancer Cell Lines
Description:
Rudiger Haugwitz (NCI)
Abstract
The present invention is directed, in general, to methods for treating human cancers and in particular to new compounds which cross the blood brain barrier and retain activity against CNS specific cancer cell lines, to pharmaceutical formulations containing such compounds, and to methods for the treatment of cancer.
The 2-methylellipticinium salts offer remarkable examples of compounds that have shown selective cytotoxicity for the CNS cancer cell lines. In 17 assays, 6 showed selectivity for the CNS subpanel at every level of the dose-response curve down to 10-7M. Both the 9-methyl and the 9-chloro analogues also displayed good CNS selectivity at the levels for growth inhibition and cytostasis.
Rudiger Haugwitz (NCI)➽ more inventions...
U.S. Pat:5,272,146issued 1993-12-21
U.S. Pat:5,441,941issued 1995-08-15
This research is described, in part, in Jurayj et al., "Design and Synthesis of Ellipticinium Salts and 1,2-Dihydroellipticines with High Selectivities against Human CNS Cancers in vitro," J. Med. Chem. 37(14):2190-2197, 1994.
Admin. Licensing Specialist (ALS),
Email:
Phone:
E-110-1992/0
Updated:Oct 1, 2005
Details
| Internal Lab Reference ID | E-110-1992/0 |
| Inventors | Rudiger Haugwitz |
1,2-Dihydroellipticines with Activity Against CNS-Specific Cancer Cell Lines
Description:
This research is described, in part, in Jurayj et al., "Design and Synthesis of Ellipticinium Salts and 1,2-Dihydroellipticines with High Selectivities against Human CNS Cancers in vitro," J. Med. Chem. 37(14):2190-2197, 1994.
Admin. Licensing Specialist (ALS),
Email:
Phone:
Abstract
The present invention is directed, in general, to methods for treating human cancers and in particular to new compounds which cross the blood brain barrier and retain activity against CNS specific cancer cell lines, to pharmaceutical formulations containing such compounds, and to methods for the treatment of cancer.
The 2-methylellipticinium salts offer remarkable examples of compounds that have shown selective cytotoxicity for the CNS cancer cell lines. In 17 assays, 6 showed selectivity for the CNS subpanel at every level of the dose-response curve down to 10-7M. Both the 9-methyl and the 9-chloro analogues also displayed good CNS selectivity at the levels for growth inhibition and cytostasis.
Rudiger Haugwitz (NCI)➽ more inventions...
U.S. Pat:5,272,146issued 1993-12-21
U.S. Pat:5,441,941issued 1995-08-15
This research is described, in part, in Jurayj et al., "Design and Synthesis of Ellipticinium Salts and 1,2-Dihydroellipticines with High Selectivities against Human CNS Cancers in vitro," J. Med. Chem. 37(14):2190-2197, 1994.
Admin. Licensing Specialist (ALS),
Email:
Phone:
E-110-1992/0
Updated:Oct 1, 2005
Details
| Internal Lab Reference ID | E-110-1992/0 |
| Inventors | Rudiger Haugwitz |
1,2-Dihydroellipticines with Activity Against CNS-Specific Cancer Cell Lines
Description:
The present invention is directed, in general, to methods for treating human cancers and in particular to new compounds which cross the blood brain barrier and retain activity against CNS specific cancer cell lines, to pharmaceutical formulations containing such compounds, and to methods for the treatment of cancer.
The 2-methylellipticinium salts offer remarkable examples of compounds that have shown selective cytotoxicity for the CNS cancer cell lines. In 17 assays, 6 showed selectivity for the CNS subpanel at every level of the dose-response curve down to 10
Abstract
The present invention is directed, in general, to methods for treating human cancers and in particular to new compounds which cross the blood brain barrier and retain activity against CNS specific cancer cell lines, to pharmaceutical formulations containing such compounds, and to methods for the treatment of cancer.
The 2-methylellipticinium salts offer remarkable examples of compounds that have shown selective cytotoxicity for the CNS cancer cell lines. In 17 assays, 6 showed selectivity for the CNS subpanel at every level of the dose-response curve down to 10-7M. Both the 9-methyl and the 9-chloro analogues also displayed good CNS selectivity at the levels for growth inhibition and cytostasis.
Rudiger Haugwitz (NCI)➽ more inventions...
U.S. Pat:5,272,146issued 1993-12-21
U.S. Pat:5,441,941issued 1995-08-15
This research is described, in part, in Jurayj et al., "Design and Synthesis of Ellipticinium Salts and 1,2-Dihydroellipticines with High Selectivities against Human CNS Cancers in vitro," J. Med. Chem. 37(14):2190-2197, 1994.
Admin. Licensing Specialist (ALS),
Email:
Phone:
E-110-1992/0
Updated:Oct 1, 2005
Details
| Internal Lab Reference ID | E-110-1992/0 |
| Inventors | Rudiger Haugwitz |
15kD Granulysin for Monocyte Differentiation: A New Immunotherapeutic for Both in vivo and ex vivo Applications
Description:
Granulysin is a cytolytic and proinflammatory molecule expressed by activated human cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. It has been implicated in many of diseases including infection, cancer, transplantation, autoimmunity, skin and reproductive maladies. Small synthetic forms of granulysin are being developed as novel antibiotics and studies suggest that granulysin may be a useful diagnostic biomarker and/or therapeutic for a wide variety of diseases.
The invention relates to methods of stimulating or enhancing an immune response using 15 kD granulysin. Investigators at the NIH have discovered that 15 kD granulysin (but not 9 kD granulysin) activates monocytes and induces them to differentiate into mature dendritic cells and activates allospecific T cells. This activation and subsequent differentiation induced by 15 kD granulysin may prove important in inducing or regulating immune responses in a host. Consequently, this invention could be used treat tumors and infections, particularly as an adjuvant for vaccines and immunotherapies. Further, this technology could be used to treat autoimmune disorders and organ transplant rejection.
Abstract
Granulysin is a cytolytic and proinflammatory molecule expressed by activated human cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. It has been implicated in many of diseases including infection, cancer, transplantation, autoimmunity, skin and reproductive maladies. Small synthetic forms of granulysin are being developed as novel antibiotics and studies suggest that granulysin may be a useful diagnostic biomarker and/or therapeutic for a wide variety of diseases.
The invention relates to methods of stimulating or enhancing an immune response using 15 kD granulysin. Investigators at the NIH have discovered that 15 kD granulysin (but not 9 kD granulysin) activates monocytes and induces them to differentiate into mature dendritic cells and activates allospecific T cells. This activation and subsequent differentiation induced by 15 kD granulysin may prove important in inducing or regulating immune responses in a host. Consequently, this invention could be used treat tumors and infections, particularly as an adjuvant for vaccines and immunotherapies. Further, this technology could be used to treat autoimmune disorders and organ transplant rejection.
Benefits
An immune response activator with broad applicability to the treatment of several diseases, including cancer, atherosclerosis, diabetes, autoimmune disorders, allergies, and infections.
-Co-administering 15kD granulysin could increase the efficacy of vaccines and immunotherapeutics.
Details
| Internal Lab Reference ID | E-158-2009/0 |
| Patent Number | PCT/US2010/052036
US Application No. 13/501,726
US |
| Inventors | Carol Clayberger (NCI) ,Alan Krensky (NCI) |
15kD Granulysin for Monocyte Differentiation: A New Immunotherapeutic for Both in vivo and ex vivo Applications
Description:
Granulysin is a cytolytic and proinflammatory molecule expressed by activated human cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. It has been implicated in many of diseases including infection, cancer, transplantation, autoimmunity, skin and reproductive maladies. Small synthetic forms of granulysin are being developed as novel antibiotics and studies suggest that granulysin may be a useful diagnostic biomarker and/or therapeutic for a wide variety of diseases.
The invention relates to methods of stimulating or enhancing an immune response using 15 kD granulysin. Investigators at the NIH have discovered that 15 kD granulysin (but not 9 kD granulysin) activates monocytes and induces them to differentiate into mature dendritic cells and activates allospecific T cells. This activation and subsequent differentiation induced by 15 kD granulysin may prove important in inducing or regulating immune responses in a host. Consequently, this invention could be used treat tumors and infections, particularly as an adjuvant for vaccines and immunotherapies. Further, this technology could be used to treat autoimmune disorders and organ transplant rejection.
Abstract
Granulysin is a cytolytic and proinflammatory molecule expressed by activated human cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. It has been implicated in many of diseases including infection, cancer, transplantation, autoimmunity, skin and reproductive maladies. Small synthetic forms of granulysin are being developed as novel antibiotics and studies suggest that granulysin may be a useful diagnostic biomarker and/or therapeutic for a wide variety of diseases.
The invention relates to methods of stimulating or enhancing an immune response using 15 kD granulysin. Investigators at the NIH have discovered that 15 kD granulysin (but not 9 kD granulysin) activates monocytes and induces them to differentiate into mature dendritic cells and activates allospecific T cells. This activation and subsequent differentiation induced by 15 kD granulysin may prove important in inducing or regulating immune responses in a host. Consequently, this invention could be used treat tumors and infections, particularly as an adjuvant for vaccines and immunotherapies. Further, this technology could be used to treat autoimmune disorders and organ transplant rejection.
Benefits
An immune response activator with broad applicability to the treatment of several diseases, including cancer, atherosclerosis, diabetes, autoimmune disorders, allergies, and infections.
-Co-administering 15kD granulysin could increase the efficacy of vaccines and immunotherapeutics.
Details
| Internal Lab Reference ID | E-158-2009/0 |
| Patent Number | PCT/US2010/052036
US Application No. 13/501,726
US |
| Inventors | Alan Krensky |
17-AAG Treatment of Diseases Sensitive to c-KIT Down Regulation
Description:
This invention describes the use of 17-allylamino-17-demethoxygeldanamycin (17-AAG), a derivative of geldanamycin, which inhibits mutated KIT protein kinase activity (the product of proto-oncogene c-KIT). This kinase has been identified as the protein responsible for transformation of certain human cell types into pathologic cells. The invention is predicated on the discovery of a new method of inhibiting the activity of a mutated, constitutively active form of the tyrosine kinase, KIT. The method involves the administration of 17-AAG to a cell expressing the mutated KIT protein, whereby the activity level of KIT in the cell is reduced. The invention may prove to be useful for treating diseases such as mastocytosis, gastrointestinal stromal tumors (GIST), mast cell leukemia, myelogenenous leukemia, and testicular cancer, all of which are associated with mutations in the c-KIT proto-oncogene.
Gerard Fumo
Abstract
This invention describes the use of 17-allylamino-17-demethoxygeldanamycin (17-AAG), a derivative of geldanamycin, which inhibits mutated KIT protein kinase activity (the product of proto-oncogene c-KIT). This kinase has been identified as the protein responsible for transformation of certain human cell types into pathologic cells. The invention is predicated on the discovery of a new method of inhibiting the activity of a mutated, constitutively active form of the tyrosine kinase, KIT. The method involves the administration of 17-AAG to a cell expressing the mutated KIT protein, whereby the activity level of KIT in the cell is reduced. The invention may prove to be useful for treating diseases such as mastocytosis, gastrointestinal stromal tumors (GIST), mast cell leukemia, myelogenenous leukemia, and testicular cancer, all of which are associated with mutations in the c-KIT proto-oncogene.
Gerard Fumo(NCI)➽ more inventions...
Leonard Neckers (NCI)➽ more inventions...
US Application No. PCT/US03/31962
Admin. Licensing Specialist (ALS),
Email:
Phone:
E-256-2002/0
Updated:May 1, 2003
Details
| Internal Lab Reference ID | E-256-2002/0 |
| Inventors | Leonard Neckers |
17-AAG Treatment of Diseases Sensitive to c-KIT Down Regulation
Description:
Leonard Neckers (NCI)
Abstract
This invention describes the use of 17-allylamino-17-demethoxygeldanamycin (17-AAG), a derivative of geldanamycin, which inhibits mutated KIT protein kinase activity (the product of proto-oncogene c-KIT). This kinase has been identified as the protein responsible for transformation of certain human cell types into pathologic cells. The invention is predicated on the discovery of a new method of inhibiting the activity of a mutated, constitutively active form of the tyrosine kinase, KIT. The method involves the administration of 17-AAG to a cell expressing the mutated KIT protein, whereby the activity level of KIT in the cell is reduced. The invention may prove to be useful for treating diseases such as mastocytosis, gastrointestinal stromal tumors (GIST), mast cell leukemia, myelogenenous leukemia, and testicular cancer, all of which are associated with mutations in the c-KIT proto-oncogene.
Gerard Fumo(NCI)➽ more inventions...
Leonard Neckers (NCI)➽ more inventions...
US Application No. PCT/US03/31962
Admin. Licensing Specialist (ALS),
Email:
Phone:
E-256-2002/0
Updated:May 1, 2003
Details
| Internal Lab Reference ID | E-256-2002/0 |
| Inventors | Leonard Neckers |
17-AAG Treatment of Diseases Sensitive to c-KIT Down Regulation
Description:
US Application No. PCT/US03/31962
Admin. Licensing Specialist (ALS),
Email:
Phone:
Abstract
This invention describes the use of 17-allylamino-17-demethoxygeldanamycin (17-AAG), a derivative of geldanamycin, which inhibits mutated KIT protein kinase activity (the product of proto-oncogene c-KIT). This kinase has been identified as the protein responsible for transformation of certain human cell types into pathologic cells. The invention is predicated on the discovery of a new method of inhibiting the activity of a mutated, constitutively active form of the tyrosine kinase, KIT. The method involves the administration of 17-AAG to a cell expressing the mutated KIT protein, whereby the activity level of KIT in the cell is reduced. The invention may prove to be useful for treating diseases such as mastocytosis, gastrointestinal stromal tumors (GIST), mast cell leukemia, myelogenenous leukemia, and testicular cancer, all of which are associated with mutations in the c-KIT proto-oncogene.
Gerard Fumo(NCI)➽ more inventions...
Leonard Neckers (NCI)➽ more inventions...
US Application No. PCT/US03/31962
Admin. Licensing Specialist (ALS),
Email:
Phone:
E-256-2002/0
Updated:May 1, 2003
Details
| Internal Lab Reference ID | E-256-2002/0 |
| Inventors | Leonard Neckers |
17-AAG Treatment of Diseases Sensitive to c-KIT Down Regulation
Description:
Updated:
Abstract
This invention describes the use of 17-allylamino-17-demethoxygeldanamycin (17-AAG), a derivative of geldanamycin, which inhibits mutated KIT protein kinase activity (the product of proto-oncogene c-KIT). This kinase has been identified as the protein responsible for transformation of certain human cell types into pathologic cells. The invention is predicated on the discovery of a new method of inhibiting the activity of a mutated, constitutively active form of the tyrosine kinase, KIT. The method involves the administration of 17-AAG to a cell expressing the mutated KIT protein, whereby the activity level of KIT in the cell is reduced. The invention may prove to be useful for treating diseases such as mastocytosis, gastrointestinal stromal tumors (GIST), mast cell leukemia, myelogenenous leukemia, and testicular cancer, all of which are associated with mutations in the c-KIT proto-oncogene.
Gerard Fumo(NCI)➽ more inventions...
Leonard Neckers (NCI)➽ more inventions...
US Application No. PCT/US03/31962
Admin. Licensing Specialist (ALS),
Email:
Phone:
E-256-2002/0
Updated:May 1, 2003
Details
| Internal Lab Reference ID | E-256-2002/0 |
| Inventors | Leonard Neckers |
Pages
Pages
Pages
NIH AREDS Lead to PreserVision Vitamins
Eye vitamins labeled as AREDS or AREDS2 refer to the results of the Age-Related Eye Disease Study, a major clinical trial sponsored by the National Eye Institute (NEI) at the National Institutes of Health. A number of manufacturers offer nutritional supplements based on these studies.
These studies reported that high levels of antioxidants and zinc could slow the progress of AMD. While the original AREDS formulation contained vitamin C, vitamin E, beta-carotene, zinc, and copper, in 2013, NEI reported the results of the follow-up AREDS2 study, where researchers tried adding omega-3 fatty acids and substituting lutein and zeaxanthin for beta-carotene (which prior studies had associated with an increased risk of lung cancer in smokers). The study found that while omega-3 fatty acids had no effect on the formulation, lutein and zeaxanthin together appeared to be a safe and effective alternative to beta-carotene. The AREDS2 formula now contains vitamin C, vitamin E, copper, lutein, zeaxanthin, and a lower amount of zinc. The AREDS formula that incorporates these vitamins isn’t a cure for AMD; however, it is extremely beneficial to anyone who has been diagnosed with intermediate or advanced AMD.
The AREDS and AREDS2 vitamins are neither a treatment nor a cure for macular degeneration. The studies showed that the formulations were most beneficial for people with:
- Intermediate age-related macular degeneration in one or both eyes, or
- Advanced age-related macular degeneration in one eye, but not the other eye
People with early stage age-related macular degeneration did not benefit from taking either AREDS formulation. AREDS does not prevent AMD from starting.
Researchers studied the following doses in AREDS and AREDS2:
- 500 milligrams (mg) of vitamin C
- 400 international units (IU) of vitamin E
- 80 mg zinc as zinc oxide (25 mg in AREDS2)
- 2 mg copper as cupric oxide
- 15 mg beta-carotene (AREDS), OR 10 mg lutein & 2 mg zeaxanthin (AREDS2)
People who smoke or have a history of smoking should avoid taking beta-carotene, also labeled as vitamin A. The AREDS2 formula with lutein and zeaxanthin is an alternative for people with a history of smoking. Lutein and zeaxanthin provide the eye the same benefits as beta-carotene without the health risks.
Before taking AREDS or AREDS2, talk to your primary care doctors and eye care professionals. They will help you determine if AREDS is best for you.
Meningococcal meningitis, a bacterial infection of the brain that sweeps across sub-Saharan Africa in an area called the “meningitis belt,” is now losing its power to inflict illness and death. Scientists and technology transfer officers from the Food and Drug Administration (FDA), along with technology transfer officers from the National Institutes of Health (NIH), made a critical contribution by developing and transferring the technology needed to manufacture a vaccine against this terrible disease and at an affordable cost for African nations like Burkina Faso, Chad, Ethiopia, and Niger. Meningitis can be prevented with vaccination, but the technology is complex and generally beyond the capacity of scientists in most developing countries.
Under a novel partnership mechanism organized by the international nonprofit PATH (Program for Appropriate Technology in Health), NIH licensed a conjugate vaccine technology developed by FDA Drs. Che-Hung Robert Lee and Carl Frasch to PATH, which worked with the Serum Institute of India, which agreed to produce the vaccine cheaply in exchange for technical know-how. The collaboration agreement was described in SciDev.net as an "intriguing model" of vaccine development in developing countries, in which a vaccine with specific characteristics tailored to a particular population is developed at a modest cost and provisions to ensure sustainable access are built in from the start.
The new vaccine, MenAfriVac, was approved by India in December 2009 for export to Africa. In June 2010, the World Health Organization had prequalified the vaccine for use in global immunization programs. By the end of 2011, an estimated 55 million people had been vaccinated with MenAfriVac at a cost of only 40 cents per dose. In 2012, a low-cost meningitis vaccine designed for use in sub-Saharan Africa without refrigeration or cold-chain custody was launched, with sales of 100 million doses.
The contribution of both the FDA and the NIH to a major health care project in Africa also underscores the recognition by both agencies that infectious diseases know no borders. Protecting human health globally is linked to the FDA’s and NIH’s core mission of protecting human health in the United States.
